David Nutt’s dismissal from the British government’s Advisory Council on the Misuse of Drugs in 2009 made a dispute over drug-risk evidence an unmistakable political confrontation. Nutt had compared psychoactive substances by their measured harms; the government’s response showed how difficult it could be to separate scientific advice from the public and political controversies surrounding drugs.

The Advisory Role and Its Stakes

Nutt, an expert on addiction and benzodiazepines such as Valium, chaired the Advisory Council on the Misuse of Drugs, the committee responsible for advising the government on how illicit drugs should be classified according to their risks to individuals and society. His work brought empirical comparison into a role with direct relevance to policy: assessments of risk were not merely academic when they could inform a drug’s official status.

Nutt’s approach produced comparisons that challenged familiar assumptions. He concluded that alcohol was more dangerous than cannabis and that using Ecstasy was safer than riding a horse. These claims made the method itself politically conspicuous: comparing drugs by assessed harm could unsettle the distinctions embedded in public discussion and drug policy.

The Public Statement and Dismissal

The decisive clash came during a live breakfast-television appearance. Asked whether he was seriously claiming that LSD was less harmful than alcohol, Nutt affirmed that he was. He later identified that televised sentence as the one that led to his dismissal from the government’s advisory post. The immediate controversy therefore centered not simply on his expertise, but on his willingness to state a comparison in public when it cut against the expected framing of LSD as especially dangerous.

The episode exposed a boundary between advising government and publicly defending the evidence behind an assessment. Nutt’s dismissal turned that boundary into the event’s central consequence: the chair of a body tasked with evaluating drug risks lost his position after articulating a risk comparison on television. The available account identifies the triggering statement and outcome, while offering no fuller account of the formal dismissal process.

A Longer History of Risk and Research

The dispute unfolded against a history in which evidence about psychedelics had repeatedly been filtered through public alarm. In the early 1960s, Sidney Cohen’s survey covered 44 researchers, about 5,000 subjects, and 25,000 occasions involving LSD or mescaline. His first assessment found few serious complications under qualified supervision; in a 1962 follow-up, he warned that casual use and irresponsible treatment were associated with serious complications and occasional catastrophic reactions. The contrasting findings illustrate why risk claims could not be reduced to a simple defense or condemnation of the drugs.

By the mid-1960s, emergency-room cases and reports of acute distress helped shift mainstream psychiatry toward treating LSD as a cause of mental illness rather than a possible treatment. In 1965 Bellevue Hospital admitted 65 people for what it called LSD-induced psychoses, while reports of harm circulated amid sensational headlines and claims that were not always borne out by later evidence. In 1966, after Sandoz withdrew LSD-25 from circulation, the Food and Drug Administration ordered researchers to stop work; many of the roughly 70 research programs then under way closed. Nutt’s 2009 controversy was not a direct continuation of those events, but it recalled the persistent difficulty of discussing psychedelic risk outside an atmosphere of public and institutional pressure.

Research Connections and Significance

The account places Nutt’s dismissal alongside the later return of psychedelic research. In 2005, Robin Carhart-Harris approached him at the University of Bristol hoping to study psychedelics and dreaming. Nutt initially judged the proposed work unrealistic, but offered Carhart-Harris a PhD beginning with a study of MDMA and the serotonin system, with psychedelic research a possible later direction. By 2009, Carhart-Harris, working in Nutt’s lab with funding from Amanda Feilding, had received approval to study psilocybin’s effects on the brain.

That research connection gives the dismissal a wider significance without making it the cause of the later studies. Nutt appears both as a public adviser punished after voicing a controversial comparison and as a mentor who helped a young researcher find a route toward psychedelic neuroscience. The contrast captures the event’s central tension: empirical inquiry could advance within research institutions even as its public expression encountered political limits.